Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNYSE:IBIONYSE:NKGNNASDAQ:PCSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.22-6.5%$0.24$0.15▼$13.00$13.07M-0.035.82 million shs2.03 million shsIBIOiBio$0.93-9.9%$0.92$0.64▼$6.89$15.33M0.96438,510 shs352,825 shsNKGNNKGen Biotech$0.33-2.2%$0.22$0.10▼$1.37$14.83M1.21.57 million shs25,934 shsPCSAProcessa Pharmaceuticals$0.26-24.0%$0.26$0.15▼$3.10$3.07M1.391.48 million shs2.99 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-7.05%+2.23%+30.30%-55.11%+21,499,900.00%IBIOiBio-9.89%-5.76%+27.47%-81.73%-63.89%NKGNNKGen Biotech-2.22%-2.94%-8.33%+94.35%-74.42%PCSAProcessa Pharmaceuticals-24.92%-14.01%+10.47%-42.17%-83.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.1295 of 5 stars3.50.00.00.00.00.00.6NKGNNKGen Biotech0.8178 of 5 stars0.05.00.00.00.62.50.0PCSAProcessa Pharmaceuticals3.1145 of 5 stars3.52.00.00.03.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,760.47% UpsideIBIOiBio 3.00Buy$4.30363.31% UpsideNKGNNKGen Biotech 0.00N/AN/AN/APCSAProcessa Pharmaceuticals 3.00Buy$6.002,221.08% UpsideCurrent Analyst Ratings BreakdownLatest PCSA, NKGN, IBIO, and ABP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K71.42N/AN/AN/A∞IBIOiBio$375K40.88N/AN/A$1.41 per share0.66NKGNNKGen Biotech$80K185.41N/AN/A($2.68) per share-0.12PCSAProcessa PharmaceuticalsN/AN/AN/AN/A$4.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbproN/AN/A0.00∞N/AN/AN/AN/AN/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APCSAProcessa Pharmaceuticals-$11.12M-$3.08N/AN/AN/AN/A-195.21%-163.06%8/12/2025 (Estimated)Latest PCSA, NKGN, IBIO, and ABP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/8/2025Q1 2025PCSAProcessa Pharmaceuticals-$0.77-$0.30+$0.47-$0.30N/AN/A3/20/2025Q4 2024PCSAProcessa Pharmaceuticals-$0.92-$0.74+$0.18-$0.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APCSAProcessa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/AN/AN/AIBIOiBio0.051.761.76NKGNNKGen BiotechN/A0.020.02PCSAProcessa PharmaceuticalsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%IBIOiBio7.90%NKGNNKGen Biotech76.17%PCSAProcessa Pharmaceuticals91.93%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%IBIOiBio0.58%NKGNNKGen Biotech10.36%PCSAProcessa Pharmaceuticals9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million4.57 millionN/AIBIOiBio10016.52 million9.82 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePCSAProcessa Pharmaceuticals2011.88 million2.84 millionNot OptionablePCSA, NKGN, IBIO, and ABP HeadlinesRecent News About These CompaniesProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025June 13 at 8:00 AM | globenewswire.comProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor ConferenceFebruary 7, 2025 | globenewswire.comProcessa Pharmaceuticals Closes $5 Million Public Offering with CEO and Institutional Investor ParticipationJanuary 30, 2025 | quiverquant.comProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.comProcessa Pharmaceuticals director David Young buys $99,288 in stockJanuary 30, 2025 | msn.comProcessa Pharmaceuticals' chief business officer buys $34,691 in stockJanuary 30, 2025 | msn.comInsider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO Acquires 87,200 Shares of StockJanuary 30, 2025 | insidertrades.comProcessa Pharmaceuticals prices $5M at-the-market offeringJanuary 29, 2025 | markets.businessinsider.comProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 27, 2025 | globenewswire.comProcessa Pharmaceuticals stock hits 52-week low at $0.65January 27, 2025 | msn.comProcessa Pharmaceuticals stock hits 52-week low at $0.8January 17, 2025 | msn.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 21, 2024 | markets.businessinsider.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 21, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCSA, NKGN, IBIO, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.22 -0.02 (-6.52%) As of 06/13/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.iBio NYSE:IBIO$0.93 -0.10 (-9.89%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.92 0.00 (-0.33%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.NKGen Biotech NYSE:NKGN$0.33 -0.01 (-2.22%) As of 06/13/2025 03:32 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Processa Pharmaceuticals NASDAQ:PCSA$0.26 -0.08 (-23.97%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.25 -0.01 (-4.84%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
